A workplace accident changed one patient’s life and began a long search for relief from severe, persistent pain. After an initial misdiagnosis, the injury was connected to a rare central nervous system disorder affecting skin, blood vessels, muscles, and bones. Pain became a near-constant part of daily life.
Through trial and error, the patient and treating physicians eventually found a combination of medications that provided some relief. Those prescriptions made ordinary activities—preparing a meal, attending an occasional function, and spending time with family—more manageable.
Some of the medicines used in that treatment were prescription opioids. These drugs require careful oversight because they can carry serious risks, including dependence, overdose, and misuse. Yet they may also remain part of an individualized treatment plan for some patients.
When safeguards become barriers
People who misuse prescription opioids may alter tablets by chewing, crushing, dissolving, or otherwise changing their intended form. Policymakers and regulators have responded with prescribing controls, monitoring programs, dispensing requirements, and other restrictions.
Those measures are intended to reduce harm, but implementation can also burden patients using medication as directed. Refill rules, repeated appointments, supply interruptions, and communication barriers between prescribers and pharmacies can disrupt continuity of care.
The policy challenge is not whether to address opioid-related harm. It is how to do so without treating every pain patient as though appropriate medical use and misuse were the same.
The role—and limits—of deterrent formulations
Abuse-deterrent formulations are designed to make certain forms of tampering more difficult or less rewarding. Depending on the product, physical or chemical properties may resist crushing, extraction, or other manipulation.
Such formulations are one tool rather than a complete answer. They do not make an opioid risk-free, prevent every form of misuse, or replace careful prescribing, patient education, monitoring, secure storage, and access to evidence-based treatment for substance use disorders.
A more balanced policy approach
A durable response should preserve clinical judgment while setting clear safety expectations. Policymakers can support access to appropriate non-opioid therapies, encourage treatment plans tailored to individual needs, and reduce abrupt interruptions that may harm stable patients.
Standards for abuse-deterrent claims should follow current federal guidance and evidence. Decisions about substitution should also account for the prescribing clinician’s directions, the patient’s circumstances, the product’s approved labeling, and applicable pharmacy rules.
Legislators, health professionals, manufacturers, insurers, pharmacies, patients, and public-health agencies each hold part of the solution. The common goal should be reducing preventable harm while ensuring that people with serious pain receive respectful, evidence-informed care.